Drug intelligence / Profile preview

XLS-101

Development stage: Preclinical
Lead developer: Xiangxue Precision Medical Technology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

XLS-101 is an autologous T-cell receptor-engineered T-cell (TCR-T) therapy being developed by Guangdong Xiangxue Precision Medical Technology (XLifeSc) for the treatment of liver cancer (hepatocellular carcinoma). The therapy involves engineering a patient's own T cells to express a T-cell receptor specific for a novel peptide derived from alpha-fetoprotein (AFP), presented in the context of HLA-A2402. This allows the modified T cells to recognize and selectively kill AFP-expressing tumor cells. XLS-101 is currently in the IND-enabling stage of development and was developed using XLifeSc's proprietary antigen peptide discovery platform.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on XLS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XLS-101.

Explore the full profile